Omnicell, Inc. - Common Stock (OMCL)

Omnicell (NASDAQ:OMCL) reported third-quarter 2026 revenue and non-GAAP EBITDA above the high end of its prior guidance, while executives said the company is preparing to begin shipments of its Titan XT automated dispensing hardware and remains on track for first-half 2027 general availability of it

EPS surpassed guidance on cost discipline and favorable customer mix.

Healthcare tech company Omnicell (NASDAQ:OMCL) announced better-than-expected revenue in Q3 2026, but revenue was flat year on year at $307.9 million. On the...

Healthcare tech company Omnicell (NASDAQ:OMCL) will be reporting earnings this Thursday before market hours. Here’s what to expect. Omnicell beat analysts’ r...

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking a...

Omnicell has been treading water for the past six months, recording a small loss of 4.6% while holding steady at $32.74. The stock also fell short of the S&P...

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas...

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...

Nnamdi Njoku's disposal reduced his direct holdings by 4%, with over half tied to tax withholding from RSU vesting. He retains ~161,223 shares worth $5.81 million.

Omnicell (NASDAQ:OMCL) reported second-quarter 2026 revenue at the high end of its prior outlook and profitability above expectations, while widening its full-year product bookings range to reflect uncertainty in the timing of customer purchasing decisions for large medication-management platform in

What Happened? Shares of healthcare tech company Omnicell (NASDAQ:OMCL) fell 9.9% in the afternoon session after the company issued weak guidance for the upc...

Healthcare tech company Omnicell (NASDAQ:OMCL) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 7.4% year on year to $312.2 million. On th...

Healthcare tech company Omnicell (NASDAQ:OMCL) will be announcing earnings results this Thursday morning. Here’s what investors should know. Omnicell beat an...

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how healthcare technology ...